Siren L.L.C. Has $39.47 Million Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Siren L.L.C. trimmed its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 12.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,829,913 shares of the company’s stock after selling 1,300,000 shares during the quarter. Taysha Gene Therapies makes up 1.1% of Siren L.L.C.’s holdings, making the stock its 27th biggest holding. Siren L.L.C.’s holdings in Taysha Gene Therapies were worth $39,470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capricorn Fund Managers Ltd acquired a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $1,650,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $1,697,000. SG Americas Securities LLC increased its holdings in shares of Taysha Gene Therapies by 2,271.8% in the fourth quarter. SG Americas Securities LLC now owns 781,474 shares of the company’s stock valued at $4,298,000 after purchasing an additional 748,525 shares during the period. Aberdeen Group plc acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $5,616,000. Finally, Rice Hall James & Associates LLC raised its stake in shares of Taysha Gene Therapies by 119.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 1,270,645 shares of the company’s stock worth $6,989,000 after purchasing an additional 692,527 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TSHA. The Goldman Sachs Group increased their price target on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday. BMO Capital Markets boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Citizens Jmp restated a “market outperform” rating and set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th. Finally, Canaccord Genuity Group lifted their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.77.

Taysha Gene Therapies Stock Up 3.0%

TSHA opened at $5.83 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies, Inc. has a 12 month low of $2.53 and a 12 month high of $7.30. The stock has a market capitalization of $1.68 billion, a P/E ratio of -15.34 and a beta of 1.17. The business has a 50 day simple moving average of $5.98 and a 200-day simple moving average of $5.36.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the sale, the insider directly owned 936,410 shares in the company, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.